Last reviewed · How we verify
Direct oral anticoagulant
Direct oral anticoagulants inhibit specific clotting factors to prevent blood clot formation.
Direct oral anticoagulants inhibit specific clotting factors to prevent blood clot formation. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention, Acute coronary syndrome (in combination with antiplatelet therapy).
At a glance
| Generic name | Direct oral anticoagulant |
|---|---|
| Also known as | DOAC, low molecular weight heparin |
| Sponsor | Centre Hospitalier Universitaire de Nīmes |
| Drug class | Direct oral anticoagulant (DOAC) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Direct oral anticoagulants (DOACs) work by directly inhibiting either Factor Xa or thrombin (Factor IIa) in the coagulation cascade, preventing the formation of fibrin clots. This class includes Factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) and direct thrombin inhibitors (dabigatran). By blocking these key enzymes, DOACs reduce thrombotic events while maintaining hemostasis.
Approved indications
- Atrial fibrillation for stroke prevention
- Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention
- Acute coronary syndrome (in combination with antiplatelet therapy)
Common side effects
- Bleeding (major and minor)
- Gastrointestinal bleeding
- Intracranial hemorrhage
- Dyspepsia
- Nausea
Key clinical trials
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- SENIOR: Stroke Prevention in the Elderly by Patent Foramen Ovale closuRe vs Anticoagulation
- AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms (PHASE3)
- A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
- Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves (PHASE3)
- Phase 3 Trial of VMX-C001 vs Usual Pharmacological Care in Patients Taking a FXa Direct Oral Anticoagulant Who Require Urgent Surgery With or Without Heparin. (PHASE3)
- REGENFAST vs L-PRF in Periodontal Regeneration (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Direct oral anticoagulant CI brief — competitive landscape report
- Direct oral anticoagulant updates RSS · CI watch RSS
- Centre Hospitalier Universitaire de Nīmes portfolio CI